KINGCA WEEK 2019

IL-7-hyFc, a long-acting recombinant IL-7 protein, generates anti-tumor activity by modulating both adaptive and innate immune cells in the tumor microenvironment

Seung-Woo Lee (POSTECH, Korea)

Towards next-generation CAR-T cell therapy for cancer

Chan Hyuk Kim (KAIST, Korea)

Immunotherapeutics in blood disease: Cytotoxic T lymphocyte therapy

Hyewon Lee (National Cancer Center, Korea)

Immune checkpoint inhibitor in lymphoma

Yoon Seok Choi (Chungnam National University College of Medicine, Korea)

Paroxysmal nocturnal hemoglobinuria in bone marrow failure

Jun Ho Jang (Sungkyunkwan University School of Medicine, Korea)

Germline mutations in inherited bone marrow failure

Jean Soulier (University Paris Diderot, France)

Telomere length and somatic mutations in aplastic anemia

Dong Soon Lee (Seoul National University School of Medicine, Korea)

Application of CRISPR/Cas-9 in blood disease

Matthew H. Porteus (Stanford Medical School, Stanford University, USA)

Gene therapy for hemophilia-will there be a new era in hemophilia treatment?

Katherine Ann High (Spark Therapeutics Inc., USA)

Stem cells in human AML

Ravi Majeti (Stanford University, USA)

Precision medicine in pediatric acute lymphoblastic leukemia

Ching-Hon Pui (St. Jude Children's Research Hospital, USA)

Treatment free remission in CML: Promise and challenges

Adam Mead (University of Oxford, UK)

Optimal treatment sequencing for patients with relapsed/refractory multiple myeloma

Ajai Chari (Mount Sinai Hospital, USA)

Current issues in the treatment of B-cell lymphoma

Seok Jin Kim (Sungkyunkwan University school of Medicine, Korea)

Treatment of Philadelphia chromosome positive acute lymphoblastic leukemia- Korean perspectives

Young Rok Do (Keimyung University School of Medicine, Korea)

Hematopoietic stem cell transplantation for adult acute lymphoblastic leukemia in Taiwan – On Behalf of TSBMT

Tran-Der Tan (Koo Foundation Sun Yat-Sen Cancer Center, Taiwan)

Adult ALL in Malaysia

Sen Mui Tan (Hospital Ampang, Malaysia)

CML in Philippines

Priscilla B. Caguioa (University of Santo Tomas Hospital, St. Luke’s Medical Center, Philippines)

Outcome of allogeneic hematopoietic stem cell transplantation for SAA and PNH at Vietnam national institute of haematology and blood transfusion

Binh Thi Thanh VO (National Institute of Hematology and Blood Transfusion, Vietnam)

Hemoglobinopathy in Thailand

Duantida Songdej (Ramathibodi Hospital, Mahidol University, Thailand)

Understanding angioimmunoblastic T-cell lymphoma: From genomics to animal pathology

Jaesang Kim (Department of Life Science, Ewha Womans University, Korea)

Genomic pathogenesis of Epstein–Barr Virus (EBV)-induced diffuse large B cell lymphoma

Sung-Yup Cho (Seoul National University College of Medicine, Korea)

Current status of precision hematology

Young-Uk Cho (University of Ulsan College of Medicine, Korea)

Clinical application of personalized medicine for AML

Joon-ho Moon (Kyungpook National University Hospital, Korea)

Immunological weapons against multiple myeloma

Je-Jung Lee (Chonnam National University Medical School, Korea)

Roles of bone marrow microenvironment in clonal evolution and drug resistance of multiple myeloma

Yusuke Furukawa (Jichi Medical University, Japan)

Antigen-mediated regulation in myeloma

Madhav V. Dhodapkar (Emory University, USA)

TK cell therapy

Maria Chiara Bonini (Università Vita-Salute San Raffaele, School of Medicine, Italy)

Updates on CAR T cell therapy for multiple myeloma

Jesús G. Berdeja (Sarah Cannon Research Institute, USA)

Accelerating personalization of immune therapies for blood cancers

Larry W. Kwak (City of Hope Comprehensive Cancer Center, USA)

Iron metabolism in hemoglobinopathies

Vip Viprakasit (Medicine Siriraj Hospital, Mahidol University, Thailand)

Deferasirox for iron overload patients: Preserving organ functions

Norbert Gattermann (Heinrich Heine University, Düsseldorf, Germany)

Management of iron overload in MDS

Heather Alice Leitch (University of British Columbia, Canada)

Genetic causes of myeloproliferative diseases: Stratification of patients and new therapeutic targets

Robert Kralovics (CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Austria)

Molecular mechanism of MPN development by mutant calreticulin

Norio Komatsu (Juntendo University School of Medicine, Japan)

Interferon in myeloproliferative neoplasms

Jean-Jacques Kiladjian (Saint-Louis Hospital and Paris 7 University, France)

Progress in gene therapy for hemophilia A and B

Glenn F. Pierce (World Federation of Hemophilia, USA)

Individualized treatment for hemophilia: Population pharmacokinetics approach

Cindy H. T. Yeung (McMaster University, Canada)

Mechanisms of cancer-associated thrombosis

Nigel Mackman (University of North Carolina, USA)

Inherited hematologic malignancies

Lucy Ann Godley (The University of Chicago, USA)

GATA2 deficiency: How to make the diagnosis? how to treat it?

Jean Donadieu (Hopital Trousseau, France)

Roles of Monosomy 7 and SAMD9/SAMD9L mutations in myeloid leukemogenesis

Hirotaka Matsui (Kumamoto University, Japan)

Mantle cell lymphoma -from the clinic to genetics

Mats Jerkeman (Lund University, Sweden)

From genetics to the clinic: Follicular lymphoma

Gilles Salles (Université Claude Bernard Lyon—1 (UCBL), France)

From genetics to the clinic of chronic lymphocytic leukemia

Wei Xu (First Affiliated Hospital of Nanjing Medical University, China)

Monoclonal antibodies in the treatment of multiple myeloma

Francesca Maria Gay (AOU Città della Salute e della Scienza, Italy)

Treatment for advanced multiple myeloma in Korea

Chang-Ki Min (College of Medicine, The Catholic University of Korea, Korea)

Experimental therapy except monoclonal antibodies

Francesca Maria Gay (AOU Città della Salute e della Scienza, Italy)

Clinical outcomes of cytogenetic high-risk multiple myeloma in Korea

Kihyun Kim, (Sungkyunkwan University School of Medicine, Korea)

EuroBloodNet: The rare anaemia disorders European epidemiological platform

María del Mar Mañú Pereira (University Hospital Vall d'Hebron, Vall d'Hebron Research Institute, Spain)

Clinical utility of high-throughput sequencing for the diagnosis of hereditary hemolytic anemia 

Myungshin Kim (College of Medicine, The Catholic University of Korea, Korea)

The molecular spectrum of hemoglobinopathy; Thalassemia and Hb variants

Cornelis Leonard Harteveld (Leiden University Medical Center, The Netherlands)

Langerhans cell histiocytosis 2019: New insights and opportunities

Carl E. Allen (Baylor College of Medicine, USA)

Treatment of HLH - today and tomorrow

Jan-Inge Henter (Karolinska Institute, Sweden)

Genetic studies on the HLH in Korea

Jong Jin Seo (University of Ulsan College of Medicine, Korea)

Pharmacogenetics in patients with childhood acute lymphoblastic leukemia

Yoichi Tanaka (Kitasato University, Japan)

Recent advances in the treatment of adult ALL

Won Sik Lee (Inje University School of Medicine, Korea)

Mutational landscape of ALL: Next-generation sequencing-based mutations scanning strategy

Seung-Tae Lee (Yonsei University College of Medicine, Korea)

Breakthroughs in the treatment of aplastic anemia

Neal Stuart Young (National Institutes of Health, USA)

Developing strategies to improve efficacy and safety of chimeric antigen receptor cell therapy

Kyung-Nam Koh (University of Ulsan College of Medicine, Korea)

New insights into poor hematopoietic reconstitution after allo-HSCT

Yuan Kong (Peking University People’s Hospital, China)

Targeting hotspot RHOA mutation in angioimmunoblastic T-cell lymphoma

Shigeru Chiba (University of Tsukuba, Japan)

Advances of CML management and the prospects for the future

Susanne Saußele (University of Mannheim, Germany)

A new paradigm shift in frontline treatment of hodgkin lymphoma

Andrea Gallamini (Medical Innovation & Statistics A. Lacassagne Cancer Center, France)

The role of the darbepoetin alfa of the treatment for Low-risk of MDS

Jun Ho Jang (Sungkyunkwan University School of Medicine, Korea)

OP01-1

RNA sequencing as an alternative tool for detecting measurable residual disease in core binding factor acute myeloid leukemia

Taehyung (Simon) Kim (University of Toronto, Canada)

OP01-2

Different predictive roles of risk group and WT1 expression in elderly AML treated by intensive chemotherapy or hypomethylating agent

Seung-Hwan Shin (The Catholic University of Korea Yeouido St. Mary's Hospital, Korea)

OP01-3

Role of plasma gelsolin protein in the final stage of erythropoiesis and in correction of myelodysplasia

Eun Jung Baek (Hanyang University Guri Hospital, Korea

OP01-4

Research use only and cell population data items from DxH800 analyzer is useful in discriminating MDS patients from those with cytopenia without MDS

Sang Hyuk Park (University of Ulsan College of Medicine, Korea)

OP01-5

Androgen therapy for lower-risk myelodysplastic syndrome

Eun-Ji Choi (University of Ulsan College of Medicine, Korea)

OP01-6

Lenalidomide as a second-Line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome (VIOLTET study)

Hawk Kim (Gachon University Gil Medical Center, Korea)

OP02-1

Pragmatic, non-interventional study of clofarabine in Korean pediatric patients with refractory or relapsed acute lymphoblastic leukemia

Jung Yoon Choi (Seoul National University College of Medicine, Korea)

OP02-2

The genotype distribution and pharmacogenetic effect on mercaptopurine dose of NUDT15 and TPMT in Korean children with acute lymphoblastic leukemia.

Hyery Kim (University of Ulsan College of Medicine, Korea)

OP02-3

Mutational profiling through exome sequencing along with MYD88 L265P analysis could facilitate the diagnosis of vitreoretinal lymphoma

Borahm Kim (Yonsei University College of Medicine, Korea)

OP02-4

Utility of MLPA as a cost effective diagnostic and prognostic method in hematological malignancies: experience of a tertiary care centre from India

Prateek Bhatia (Post Graduate Institute of Medical Education and Research, Chandigarh, India)

OP02-5

Genetic characteristics and long-term outcomes of Korean adult patients with Ph-Like ALL versus non-Ph-Like ALL

Jae-Ho Yoon (The Catholic University of Korea Seoul St. Mary's Hospital, Korea

OP02-6

Outcomes after second allogeneic hematopoietic cell transplantation in relapsed acute lymphoblastic leukemia: A single-center experience

Seug Yun Yoon (The Catholic University of Korea Seoul St. Mary's Hospital, Korea

OP03-1

Diffuse large B-Cell lymphomas carrying chromosomal abnormalities showed a poor prognosis despite aggressive treatment

Gi June Min (The Catholic University of Korea Seoul St. Mary's Hospital, Korea)

OP03-2

Telomere length and its correlation with gene mutations in chronic lymphocytic leukemia in a Korean population

Da Young Song (Seoul National University Hospital, Korea)

OP03-3

International prognostic index improves prognostic value of interim PET-CT Scans in diffuse large B-Cell lymphoma

Ho - Young Yhim (Chonbuk National University Hospital, Korea)

OP03-4

Screening for monoclonal B-Lymphocytes expansions in a hospital-based Chinese population with lymphocytosis

Jiadai Xu (Zhongshan Hospital, Fudan University, China)

OP03-5

Peripheral T Cell lymphoma - Demographic profile and outcomes : 17 years experience from tertiary cancer centre, India

Siva Sree Kesana (Cancer Institute (WIA), India)

OP03-6

A multicenter retrospective analysis of clinicopathologic features of monomorphic epitheliotropic intestinal T-Cell lymphoma

Jun Ho Yi (Chung-Ang University, Korea)

OP04-1

Autophagy and unfolded protein response as the regulatory mechanism for the sensitivity of leukemia stem cells to G9a inhibitor

Ji Eun Jang (Yonsei University College of Medicine, Korea)

OP04-2

3-Methyladenine potentiates bortezomib-induced apoptosis of myeloma cell via increasing mitochondrial ROS through autophagy inhibition

Chu Myong Seong (Ehwa Womans University Mokdong Hospital, Korea)

OP04-3

Adoptive transfer of type 1-regulatory T Cell ameliorates GVHD by partial differentiation into Foxp3+CD4+T Cell with CTLA-4 and ICOS dependent manner

Young-Woo Jeon (Catholic Hematology Hospital, Korea)

OP04-4

Understanding thrombocytopenia: Role of MicroRNA In neonatal and adult megakaryopoiesis

Ravi Kumar Gutti (University of Hyderabad, India)

OP04-5

The expression level of prohibitin 2 as mitochondrial autophage receptor matches the prognostic chromosomal aberrations of hematological malignancies

Junhyung Lee (Chonnam National University Hwasun Hospital, Korea)

OP04-6

Epigallocatechin gallate suppresses interleukin-1β Secretion by inhibition of NLRP3 inflammasome

Cheng Zhang (Qilu Hospital, Shandong University, China)

OP05-1

HLA-G-ILT2 interaction contribute to suppression of marrow B-Cell growth in acquired aplastic anemia

Peng Chen (Qilu Hospital of Shandong University, China)

OP05-2

A Phase 3, multicenter, noninferiority study of ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors

Jong Wook Lee (The Catholic University of Korea Seoul St. Mary's Hospital, Korea)

OP05-3

Prediction of thrombosis risk in patients with Paroxysmal nocturnal hemoglobinuria

Yuzhou Huang (Peking Union Hospital, China)

OP05-4

High prevalence of anemia in elderly in South Korea: Urgent health-care problem before post-aged society- base on data from the KNHANES

Hee Won Chueh (Dong-A University College of Medicine, Korea)

OP05-5

Vitamin-D and biochemical status in young children with Beta-Thalassemia major

Uet YU (Shenzhen Children's Hospital, China)

OP05-6

Application of rapamycin up-regulating treg cell ratio in children with chronic refractory immune cytopenia - A singlecenter case series

Hao Gu (Beijing Children Hospital, Capital Medical University, China)

OP06-1

Predictive role of circulating immune cell subtypes early after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia

Sung - Soo Park (The Catholic University of Korea Seoul St. Mary's Hospital, Korea)

OP06-2

Sibling umbilical cord blood transplantation as a treatment for beta thalassemia major in pediatric patients

Xiaodong Wang (Shenzhen Children'S Hospital, China)

OP06-3

The outcome of hematopoietic stem cell transplantation (HSCT) in pediatric patients with hemophagocytic lymphohistiocytosis (HLH) in Korea

Jun Eun Park (Ajou University School of Medicine, Korea)

OP06-4

HLA-haploidentical transplantation for thalassemia major using NF-08-TM haploid regimen

Xiaoling Zhang (Shenzhen Children'S Hospital, China)

OP06-5

Comparison of haploidentical and umbilical cord blood transplantation using targeted busulfan in children and adolescent with hematologic malignancies

Kyung Taek Hong (Seoul National University Hospital, Korea)

OP06-6

Different circulating T cells are associated with early relapse after autologous HSCT in patients with multiple myeloma and classical hodgkin lymphoma

Egor Batorov (Research Institute of Fundamental And Clinical Immunology, Russia)

OP07-1

Molecular abnormalities and their correlation with the prognosis of younger Indian patients with de novo myelodysplastic syndromes: AIIMS study

Dr Rekha Chaubey (AIIMS, India)

OP07-2

Immunogenic cell death in acute myeloid leukemia: Synergy with Venetoclax

Marc Diederich (Seoul National University, Korea)

OP07-3

Prediction of clinical outcomes with assessment of sarcopenia and adipopenia by computed tomography in adult patients with acute myeloid leukemia

Jongheon Jung (National Cancer Center, Korea)

OP07-4

Hyperleukocytosis at initial diagnosis of AML: Cytogenetic and molecular feature and prognostic implication in patients undergoing allogeneic-HSCT

Silvia Park (The Catholic University of Korea Seoul St. Mary's Hospital, Korea)

OP07-5

Germline predisposition gene mutations in pediatric acute myeloid leukemia

Dajeong Jeong (Seoul National University College of Medicine, Korea)

OP07-6

HSCT is an effective method to improve the prognosis of AML in children with c-Kit mutationanalysis of 131 cases

Li Gao (Children'S Hospital of Soochow University, China)

OP08-1

Next-generation sequencing study of V(D)J rearrangements on Non-CR patients showing MRD negativity by next-generation flow

Naery Yang (Seoul National University College of Medicine, Korea)

OP08-2

Bone marrow tracer uptake pattern of PET/CT in multiple myeloma: Image interpretation criteria and prognostic value

Jing Li (Zhongshan Hospital, Fudan University, China)

OP08-3

Real world experience of carfilzomib, and dexamethasone versus pomalidomide-Based combination chemotherapy after a 2nd-Line therapy in RRMM

Ji Hyun Lee (Dong-A University Hospital, Korea)

OP08-4

PD-1 blockade reinvigorates bone marrow CD8+ T cells from multiple myeloma patients in the presence of TGF-Β inhibition

Yoon Seok Choi (Chungnam National University College of Medicine, Korea)

OP08-5

A multicenter, phase II study of response-adapted lenalidomide-Based therapy for elderly patients with newly diagnosed multiple myeloma in Korea

Kwai Han Yoo (Gachon University Gil Medical Center, Korea)

OP08-6

Preclinical and clinical results of combination immunotherapy; Cancer vaccine with immune modulator, checkpoint inhibitors and epigenetic regulator

Jooeun Bae (Harvard Medical School, USA)

OP09-1

Clinical features and treatment outcomes of hodgkin lymphoma: A retrospective review in a Malaysian tertiary centre

Yang Liang Boo (Hospital Sultanah Aminah, Malaysia)

OP09-2

Primary central nervous system lymphoma : An institutional experience from India with uniform chemotherapy protocol

Pooja Gogia (Senior Resident, India)

OP09-3

Busulfan, etoposide, cytarabine and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin

Jae - Cheol Jo (Ulsan University Hospital, University of Ulsan College of Medicine, Korea)

OP09-4

Predictive parameters for neutropenia after R-CHOP chemotherapy with prophylactic peg G-CSF in patients with diffuse Large B-Cell lymphoma

Do Young Kim (Pusan National University Hospital, Korea)

OP09-5

Clinical characteristics of childhood hemophagocytic syndrome and analysis of underlying genetic deficiency

Huirong Mai (Shenzhen Children'S Hospital, China)

OP09-6

Identification of genetic mutation in pediatric patients with HLH : The study of Korean clinical research network for histiocytosis

Hyery Kim (University of Ulsan College of Medicine, Korea)

OP10-1

An epidemiologic study for disease transformation and second cancers in Korean patients with myeloproliferative neoplasms

Junshik Hong (Seoul National University Hospital, Korea)

OP10-2

The temporal sequence and the differences of somatic mutation acquisition determines clinical behaviors of JAK2 positive myeloproliferative neoplasms

Ja Min Byun (Seoul National University Boramae Medical Center, Korea)

OP10-3

Retrospective screening for myeloproliferative neoplasms in patients with cerebral infarctions as revealed using the revised 2016 WHO criteria

Ik-Chan Song (Chungnam National University Hospital, Korea)

OP10-4

Clinical characteristics and risk groups of chronic myeloid leukemia in children

Quoc Thanh Nguyen (University of Medicine And Pharmacy In Ho Chi Minh City, Vietnam)

OP10-5

Expression and clinical significance of PTEN gene in chronic myeloid leukemia (CML) Patient in Indian population

Asgar Ali (All India Institute of Medical Sciences Patna, Bihar, India)

OP10-6

Pilot prospective phase II study of Nilotinib combined by chemotherapy for myeloid blastic phase of chronic myeloid leukemia or bcr-Abl positive acute

Hawk Kim (Gachon University Gil Medical Center, Korea)

OP11-1

Single-Center clinical data analysis of hereditary thrombocytopenia in children with chronic thrombocytopenia

Jingyao Ma (Beijing Children'S Hospital, Capital Medical University, National Center of Children‘s Health, China, China)

OP11-2

Developing a diagnostic predictive model for immune thrombocytopenic purpura based on immature platelet fraction

Min Ji Jeon (Korea University Guro Hospital, Korea)

OP11-3

Insufficient receptor editing leads to B cell central intolerance and subsequent autoantibodies accumulation in primary immune thrombocytopenia

Zi Sheng (Qilu Hospital, Shandong University, China

OP11-4

ROTEM Parameters as predicting factors for bleeding in immune thrombocytopenic purpura

Huu Tuan Nguyen (Cho Ray Hospital, Vietnam)

OP11-5

Increased pathogenic Th17 cells in primary immune thrombocytopenia

Ju LI (Qilu Hospital, Shandong University, China)

OP11-6

Prediction value of risk assessment model deep vein thrombosis with padua prediction score

Iswandi Darwis (Lecturer and Clinician on Faculty of Medicine, Lampung University, Indonesia)

OP12-1

Cytoprotective autophagy in bone marrow endothelial cells enhance hematopoietic stem cells in poor graft function patients after allo-Transplant

Xie - Na Cao (Peking University People’S Hospital, China

OP12-2

Aberrant bone marrow M1/M2 macrophage polarization may contribute to prolonged isolated thrombocytopenia after allotransplantation

Hong - Yan Zhao (Peking University, China)

OP12-3

G-CSF-induced macrophage polarization may prevent acute graft-versus-host disease after allogeneic hematopoietic stem cell transplant

Qi Wen (Peking University People’S Hospital, China)

OP12-4

Early transplantation-related mortality within 50 days after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia

Seom Gim Kong (Kosin University Gospel Hospital, Korea)

OP12-5

Incidence of anicteric veno-occlusive disease/sinusoidal obstruction syndrome and defibrotide efficacy following hematopoietic stem cell transplant

Richard Martin (Jazz Pharmaceuticals, UK)

OP12-6

Phase I trial of repeated infusions of bone-marrow derived mesenchymal stem cells in steroidrefractory chronic graft-versus-host disease patients

Nayoun Kim (The Catholic University of Korea Seoul St. Mary's Hospital, Korea)

Deep learning for CRISPR-Cpf1 research

Sungroh Yoon (Seoul National University, College of Engineering, Korea)

Precision dinner: Genomes and health records

Ju Han Kim (Seoul National University College of Medicine, Korea)

Connected health and wellness journey

Jack Ahn (Samsung Electronics, USA)

Genomics of core-binding factor AML

Nicolas Duployez (Lille University Hospital, France)

Precision medicine in AML in the era of novel agents

Gail J. Roboz (Weill Medical College of Cornell University, USA)

Incorporation of molecular assessments in risk stratification for myelodysplastic syndromes: Ready for prime time?

Amer M. Zeidan (Yale University, USA)

Is chronic myeloid leukemia a single hit disorder?: Evidence from next-generation sequencing data

Dennis Kim (University of Toronto, Princess Margaret Cancer Centre, Canada)

NGS-based ABL1 kinase domain mutation detection

Simona Soverini (University of Bologna, Italy)

Precision medicine and immunity in CML

Satu Mustjoki (University of Helsinki, Finland)

Early “Goal-directed Coagulation Therapy” approaches for the management of acute trauma-hemorrhage and trauma-induced coagulopathy

Marc Guido Maegele (Witten/Herdecke University, Germany)

Clinical application of clot waveform analysis in hemophilia treatment

Keiji Nogami (Nara Medical University, Japan)

Thrombin generation assay

Bas de Laat (Synapse Research Institute, The Netherland)

Europe's experience of treatment-free remission in CML

Susanne Saußele (University of Mannheim, Germany)

Korea's experience of treatment-free remission in CML

Hawk Kim (Gachon University College of Medicine, Korea)

TKI-related cardiovascular toxicities in Europe

Susanne Saußele (University of Mannheim, Germany)

Long-term safety of tyrosine kinase inhibitors in chronic myeloid leukemia patients

Jee Hyun Kong (Yonsei University College of Medicine, Korea)

Treatment of childhood ALL with IKZF1 deletion (Malaysia-Singapore ALL 2010 Study)

Allen Yeoh Eng Juh (National University of Singapore, Singapore)

Multicenter clinical trial of pediatric acute lymphoblastic leukemia in China: CCLG 2008 study

Chi-kong Li (The Chinese University of Hong Kong, Hong Kong)

Recent updates of prospective trials for ALL in Japan

Yasuhiro Okamoto (Kagoshima University Graduate School of Medical and Dental Sciences, Japan)

Pathogenesis of EBV-associated lymphoproliferative disorders

Hiroshi Kimura (Nagoya University Graduate School of Medicine, Japan)

Molecular understanding of peripheral T-cell lymphoma

Javeed Iqbal (University of Nebraska Medical Center, USA)

Clinical application of cell-free DNA in lymphoma

Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea)

Droplet microfluidics in antibody discovery, immune repertoire sequencing and personalized cancer therapy

Christoph A. Merten (European Molecular Biology Laboratory (EMBL), Germany)

Applications of single-cell mass cytometry in hematologic malignancies

Gregory Behbehani (The Ohio State University– the James Cancer Center, USA)

Prediction of acute myeloid leukemia risk in healthy individuals

Liran I. Shlush (Weizmann Institute of Science, Israel)

The new genomics of acute lymphoblastic leukemia

Charles G. Mullighan (St. Jude Children’s Research Hospital, USA)

Genomics in MM (Genomics in multiple myeloma)

Gareth Morgan (Center for Myeloma Research, Institute of Cancer Research, USA)